Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from AstraZeneca ( (GB:AZN) ) is now available.
AstraZeneca has confirmed that as of 28 February 2026 its issued share capital with voting rights stands at 1,550,966,708 ordinary shares, with no shares held in treasury, resulting in an identical total number of voting rights. This figure provides the reference denominator required under U.K. disclosure rules for investors to assess when they must report holdings or changes in their interest in AstraZeneca, reinforcing transparency around the company’s ownership structure and regulatory compliance.
By clarifying the official voting-rights total, the company offers investors and regulatory bodies a precise basis for monitoring significant shareholdings and governance influence. The update, a routine but important disclosure under the Financial Conduct Authority’s transparency regime, supports orderly market functioning and ensures stakeholders can track shifts in AstraZeneca’s shareholder base against a clearly stated capital structure.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company focused on discovering, developing and commercialising prescription medicines in oncology, rare diseases and broader biopharmaceuticals, including cardiovascular, renal, metabolism, respiratory and immunology. Headquartered in Cambridge, U.K., its medicines are sold in more than 125 countries and used by millions of patients worldwide.
For an in-depth examination of AZN stock, go to TipRanks’ Overview page.